SAP interacts with CD28 to inhibit PD-1 signaling in T lymphocytes.


Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
08 2020
Historique:
received: 01 10 2019
revised: 19 05 2020
accepted: 26 05 2020
pubmed: 7 6 2020
medline: 2 2 2021
entrez: 7 6 2020
Statut: ppublish

Résumé

T cell co-stimulation is important for the maintenance of immunologic tolerance. Co-inhibitory receptors including programmed cell death-1 (PD-1) confer peripheral tolerance to prevent autoimmunity. SAP (SH2D1A) is an adaptor molecule that is important in T cell signaling and has been shown to interact with signaling lymphocytic activation molecule (SLAM) family receptors also in the context of self-tolerance. We recently reported that SAP interferes with PD-1 function. In the current study, we investigated the levels of SAP and PD-1 in patients with rheumatoid arthritis (RA) to further understand what role they play in disease activity. We observed increased SAP levels in lymphocytes of RA patients and found that PD-1 levels correlated positively with RA disease activity. Additionally, we found that SAP interacts with CD28 to inhibit T cell signaling in vitro. This work demonstrates a putative molecular mechanism for SAP mediated PD-1 inhibition.

Identifiants

pubmed: 32504780
pii: S1521-6616(19)30531-5
doi: 10.1016/j.clim.2020.108485
pmc: PMC9278890
mid: NIHMS1603825
pii:
doi:

Substances chimiques

CD28 Antigens 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0
SH2D1A protein, human 0
Signaling Lymphocytic Activation Molecule Associated Protein 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

108485

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI125640
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150597
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA231277
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that there are no competing interests.

Références

Clin Exp Immunol. 2017 Jun;188(3):455-466
pubmed: 28245522
Scand J Rheumatol. 2006 Jul-Aug;35(4):268-72
pubmed: 16882589
Cell Rep. 2019 Jun 11;27(11):3315-3330.e7
pubmed: 31189114
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Nature. 2017 Feb 1;542(7639):110-114
pubmed: 28150777
J Immunol. 2001 May 1;166(9):5480-7
pubmed: 11313386
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E468-E477
pubmed: 29282323
J Hum Genet. 2007;52(6):557-560
pubmed: 17468813
Nat Genet. 2013 Jun;45(6):670-5
pubmed: 23603763
J Clin Invest. 2018 Oct 1;128(10):4669-4681
pubmed: 30198907
Science. 2017 Mar 31;355(6332):1423-1427
pubmed: 28280249
N Engl J Med. 2003 Nov 13;349(20):1907-15
pubmed: 14614165
Z Rheumatol. 2015 Apr;74(3):230-9
pubmed: 24942602
J Immunol. 1997 Sep 15;159(6):2986-93
pubmed: 9300723
Clin Exp Rheumatol. 2007 Sep-Oct;25(5 Suppl 46):S4-11
pubmed: 17977483
Genome Med. 2018 Dec 20;10(1):97
pubmed: 30572963
Genes Immun. 2005 Aug;6(5):430-7
pubmed: 15959535
EMBO J. 2002 Feb 1;21(3):314-23
pubmed: 11823424
Front Immunol. 2017 Jul 24;8:851
pubmed: 28791012
Arthritis Rheum. 2005 Apr;52(4):1058-62
pubmed: 15818672
Front Immunol. 2015 Jul 27;6:384
pubmed: 26284069
Front Immunol. 2017 Mar 20;8:300
pubmed: 28373873
Cell Rep. 2018 Jul 10;24(2):379-390.e6
pubmed: 29996099
Nat Genet. 2009 Dec;41(12):1313-8
pubmed: 19898481
Nat Rev Immunol. 2009 Jan;9(1):39-46
pubmed: 19079134
Science. 2017 Mar 31;355(6332):1428-1433
pubmed: 28280247
Mol Med Rep. 2018 Feb;17(2):3297-3305
pubmed: 29257239
Rheum Dis Clin North Am. 1990 Aug;16(3):513-37
pubmed: 2217956
J Exp Med. 1994 Mar 1;179(3):1071-6
pubmed: 7509360
Int Immunol. 2001 Apr;13(4):559-65
pubmed: 11282995

Auteurs

Sabina Sandigursky (S)

Department of Medicine, NYU School of Medicine, New York, NY 10016, USA.

Mark R Philips (MR)

Department of Medicine, NYU School of Medicine, New York, NY 10016, USA.

Adam Mor (A)

Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY 10032, USA. Electronic address: am5121@cumc.columbia.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH